Clinical trials: Recurrent Rectal Carcinoma
Recurrent Rectal Cancer
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
The study is a prospective, single-center, single-arm, two-cohort, phase II clinical trial. Patients aged 18 years or older who had pelvic recurrence rectal cancer with or without resectable distant metastasis, with treatment…
- Trial name
- TORCH-R (NCT05628038)
- Testing
- PD-1 antibody, Capecitabine, 5FU
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Fudan University
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Adrenocortical Carcinoma, Breast Cancer
Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT00003038
- Testing
- doxorubicin hydrochloride, suramin
- Where
- United States
- Sponsor
- Mayo Clinic
Inoperable or Recurrent Rectal Cancer
A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer
The pilot study is designed to investigate the value of Neo-adjuvant Tomudez in combination with radiotherapy in patients with inoperable or recurrent rectal cancer in terms of response rate and increasing the resectability of…
- Trial name
- TOMUDEX (NCT00590278)
- Testing
- Tomudex, Radiotherapy, Haematology
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Melanoma, Solid Tumor
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of…
- Conditions
- Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer
- Trial name
- NCT07121829
- Testing
- Tovorafenib, Tovorafenib Drug: Pimasertib
- Where
- 10 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Recurrent Colon Cancer, Liver Metastases
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Conditions
- Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00019760
- Testing
- floxuridine, leucovorin calcium, melphalan
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Colorectal Cancer
Aspirin and/or Folic Acid in Preventing Recurrent Colorectal Polyps
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of aspirin and/or folic acid may be effective in preventing recurrent polyps in patients who have…
- Trial name
- NCT00033319
- Testing
- folic acid, acetylsalicylic acid
- Where
- 32 sites in United Kingdom
- Sponsor
- Queen's Medical Center
Colorectal Cancer, Metastatic Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ERBIFORT (NCT00557102)
- Testing
- cetuximab, filgrastim, fluorouracil
- Where
- France
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute, France
Colorectal Cancer
Cetuximab in Treating Patients With Stage IV Colorectal Cancer
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00020930
- Testing
- cetuximab
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer, Triple Negative Breast Cancer
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
The purpose of this trial is to evaluate changes in immune activity relative to baseline following treatment with Toca 511 and Toca FC in patients with solid tumors (including recurrent high grade glioma [rHGG]) or lymphoma.
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT02576665
- Testing
- Toca 511, Toca FC
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tocagen Inc.
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cryosurgery kills cancer cells by freezing them.
- Trial name
- NCT00008294
- Testing
- FOLFOX regimen, dexamethasone, floxuridine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Cancer, Recurrence
Re-irradiation for Pelvic Recurrences in Rectal Cancer Patients
This study investigates the potential benefit of re-irradiation of patients with locally advanced rectal recurrences, by a prospective phase II clinical, imaging and translational research study.
- Conditions
- Rectal Cancer, Recurrence, Radiation Toxicity
- Trial name
- Re-RAD-I (NCT05816980)
- Testing
- Hyperfractionated external beam radiation
- Where
- 2 sites in Denmark, Norway
- Volunteers
- 16 people
- Sponsor
- Aarhus University Hospital
Colorectal Cancer
Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Monoclonal antibodies can find and locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003543
- Testing
- monoclonal antibody A33, carmustine, fluorouracil
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as S-1, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00974389
- Testing
- bevacizumab, tegafur-gimeracil-oteracil potassium
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Osaka Medical College
Rectal Cancer
Randomized Clinical Trial on Preoperative Radiotherapy 25 Gy in Rectal Cancer
The purpose of this study is to establish the influence of time-interval between preoperative hyperfractionated radiotherapy (5x5 Gy) and surgery on long term overall survival (5 years), local and distant recurrence rate…
- Trial name
- NCT01444495
- Testing
- Preoperative radiotherapy, Surgery
- Where
- Poland
- Volunteers
- 154 people
- Sponsor
- Jagiellonian University
Colorectal Cancer
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00055822
- Testing
- oblimersen sodium, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Rectal Cancer
Computer Navigation-assisted Surgery for Locally Advanced and Recurrent Rectal Cancer
The aim of this study is to investigate feasibility of computer navigation-assisted surgery in particularly difficult cases of locally advanced (LARC) and recurrent (LRRC) rectal cancer where the standard surgical strategy is…
- Trial name
- NAVI-LARRC (NCT04512937)
- Testing
- Computer-assisted navigation surgery
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Colorectal Cancer
FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00077337
- Testing
- romidepsin
- Where
- 88 sites in United States
- Sponsor
- SWOG Cancer Research Network
Colorectal Cancer
Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897754
- Testing
- gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction
- Volunteers
- 200 people
- Sponsor
- ECOG-ACRIN Cancer Research Group